NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
72603-0256-01 | 72603-0256 | Everolimus | EVEROLIMUS | 7.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Oct 1, 2024 | In Use | |
00378-3098-85 | 00378-3098 | Everolimus | Everolimus | 7.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Dec 15, 2022 | Feb 28, 2025 | In Use |
70377-0012-23 | 70377-0012 | Everolimus | EVEROLIMUS | 7.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | May 17, 2024 | In Use | |
62935-0756-80 | 62935-0756 | Leuprolide acetate | Eligard | 7.5 mg/.25mL | Hormonal Therapy | GnRH Agonist | Subcutaneous | Nov 1, 2023 | In Use | ||
70383-0073-01 | 70383-0073 | MOTIXAFORTIDE ACETATE | Aphexda | 62.0 mg/1.7mL | Ancillary Therapy | Immunostimulant | Stem cell mobilizer | Subcutaneous | Sep 8, 2023 | In Use | |
82737-0073-01 | 82737-0073 | Motixafortide | Aphexda | 62.0 mg/1.7mL | Ancillary Therapy | Immunostimulant | Stem cell mobilizer | Subcutaneous | Sep 8, 2023 | In Use | |
00078-0958-19 | 00078-0958 | tisagenlecleucel | KYMRIAH | 60000000.0 1/1 | Immunotherapy | CAR-T | CD19 | Intravenous | May 1, 2018 | In Use | |
55150-0386-00 | 55150-0386 | CARBOPLATIN | CARBOPLATIN | 600.0 mg/60mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Aug 3, 2020 | In Use | |
55150-0386-01 | 55150-0386 | CARBOPLATIN | CARBOPLATIN | 600.0 mg/60mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Aug 3, 2020 | In Use | |
50742-0448-60 | 50742-0448 | Carboplatin | Carboplatin | 600.0 mg/60mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jul 1, 2023 | No Longer Used | |
82511-0006-60 | 82511-0006 | CARBOPLATIN | CARBOPLATIN | 600.0 mg/60mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Aug 24, 2023 | In Use | |
55513-0004-04 | 55513-0004 | Darbepoetin alfa | Aranesp | 60.0 ug/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Sep 11, 2006 | In Use | ||
55513-0004-01 | 55513-0004 | Darbepoetin alfa | Aranesp | 60.0 ug/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Sep 11, 2006 | In Use | ||
55513-0023-04 | 55513-0023 | Darbepoetin alfa | Aranesp | 60.0 ug/.3mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Aug 14, 2006 | In Use | ||
55513-0023-01 | 55513-0023 | Darbepoetin alfa | Aranesp | 60.0 ug/.3mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Feb 18, 2011 | In Use | ||
55513-0710-01 | 55513-0710 | Denosumab | Prolia | 60.0 mg/mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Jun 5, 2010 | In Use | |
55513-0710-21 | 55513-0710 | Denosumab | Prolia | 60.0 mg/mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Mar 5, 2024 | In Use | |
59212-0601-22 | 59212-0601 | alitretinoin | PANRETIN | 60.0 mg/60g | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Topical | Sep 10, 2019 | In Use | |
62856-0601-22 | 62856-0601 | Alitretinoin | Panretin | 60.0 mg/60g | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Topical | Feb 3, 2009 | Oct 31, 2021 | No Longer Used |
76075-0101-01 | 76075-0101 | Carfilzomib | Kyprolis | 60.0 mg/30mL | Chemotherapy | Proteasome Inhibitor | 20S | Intravenous | Jul 20, 2012 | In Use | |
14789-0013-10 | 14789-0013 | Busulfan | Busulfan | 60.0 mg/10mL | Chemotherapy | Alkylating Agent | Alkylsulfonate | Intravenous | Sep 15, 2023 | Jul 21, 2024 | No Longer Used |
00002-4165-02 | 00002-4165 | Raloxifene Hydrochloride | Evista | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Jan 6, 1998 | Dec 31, 2017 | No Longer Used | |
72241-0010-22 | 72241-0010 | Raloxifene hydrochloride | Raloxifene hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Dec 30, 2017 | In Use | ||
65162-0057-03 | 65162-0057 | Raloxifene Hydrochloride | Raloxifene Hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Jan 20, 2016 | In Use | ||
72162-2418-03 | 72162-2418 | Raloxifene hydrochloride | Raloxifene hydrochloride | 60.0 mg/1 | Hormonal Therapy | Selective Estrogen Receptor Modulator (SERM) | Oral | Oct 31, 2024 | In Use |
Found 11398 results — Export these results